CureApp and Jichi Medical University Collaborate on a Hypertension Therapeutics App: Primary Endpoint Met in Phase III Clinical Trial in Japan
CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake; hereafter “the Company”) has completed a Japanese Phase III multicenter randomized controlled trial of their digital therapeutics (“DTx”) app to treat hypertension, which was jointly researched by a team led by Professor Kazuomi Kario at Jichi Medical University. Results of this study showed a statistically significant difference in average systolic blood pressure*1 over a 24-hour period – the primary endpoint of this study, demonstrating a hypotensive effect. Moving forward, the Company will seek regulatory approval based on the results of this study.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005504/en/
CureApp and Jichi Medical University collaborate on a hypertension therapeutics app: Primary endpoint met in Phase III clinical trial in Japan (Graphic: Business Wire)
Summary of the clinical trial and efficacy of the hypertension therapeutics app
Commencing in December 2019, this trial*2 evaluated the efficacy and safety of the DTx app when used with patients with essential hypertension who had not received oral treatments using antihypertensive drugs. For this comparative study, subjects were divided into two groups. This included a control group that only applied lifestyle changes based on the Guidelines for the Management of Hypertension 2019 (hereafter, “the Guidelines”)*3, and an intervention group using the DTx app in addition to the lifestyle changes proposed in the Guidelines.
As a result, the intervention group showed a statistically significant difference from the control group in the “deviation from the baseline in the average systolic blood pressure over a 24-hour period as measured by ambulatory blood pressure monitoring (ABPM)*4 in the 12th week of the study” – the primary endpoint. This demonstrates that the DTx app had a marked effect in treating hypertension. The results from this study will be presented in detail at conferences and in papers at a later date to be notified separately.
The potential of therapeutics for hypertension
Hypertension is the highest risk factor for cerebral and cardiovascular diseases (stroke and heart disease). An estimated 100,000 people*5 die of hypertension-induced cerebral and cardiovascular diseases every year. In Japan, hypertension is found in some 43 million people*3, and medical costs associated with hypertension have ballooned to around 1.7 trillion yen*6. Despite this, only around 10 million people*7 are said to receive continuous treatment for hypertension, less than one-quarter of the total affected.
While lifestyle improvements are vital for treating hypertension, maintaining such changes is dependent on a patient’s values and motivation, their workplace and home environment, and other factors. This presents challenges for effective intervention by medical institutions. There is also a subset of patients that wish to avoid medication who struggle with reducing their blood pressure. In response to these issues, this DTx app automatically delivers treatment guidance personalized to the individual (optimal nutritional, exercise, and sleeping advice based on an IoT blood pressure monitor and lifestyle habit logs, and notifications prompting behavioral changes) directly to the patient. This form of treatment helps reduce hypertension without the use of medication by encouraging changes in mindset and behavior, and aiding patients in adopting appropriate lifestyle habits.
*1 Systolic blood pressure: High blood pressure measured in blood pressure measurements.
*2 Kario K. Nomura A. Satake K. et al. A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB-DH1 trial. J Clin Hypertens. (Greenwich) 2020;22(9):1713-1722 https://doi.org/10.1111/jch.13993
*3 Guidelines for the Management of Hypertension 2019 [JSH2019]; The Japanese Society of Hypertension (2019) https://www.jpnsh.jp/guideline.html
*4 Ambulatory blood pressure monitoring (ABPM): Continuous blood pressure measurements taken at predetermined intervals over a 24 hour period during the course of one’s daily life. This helps determine variations in blood pressure (variation patterns over the course of a day). This is important due to the various factors which may alter one’s blood pressure.
*5 “Vital Statistics Summary”2019 Study (Ministry of Health, Labour and Welfare)
*6 “Medical Care Expenditure Summary” 2018 Study (Ministry of Health, Labour and Welfare)
*7 “Patient Study”2017 Study (Ministry of Health, Labour and Welfare)
Department of Cardiovascular Medicine, Jichi Medical University
Professor Kazuomi Kario
The fact that the world’s first hypertension therapeutics app was able to produce a hypotensive effect with relation to the average systolic blood pressure over a 24-hour period – a key evaluation item of this Phase III clinical study (trial) – represents a significant step forward for hypertension treatment. When treating hypertension, reducing the risk of serious complications through therapeutic intervention and reducing blood pressure at an early stage is vital. Treatment is based on reducing salt intake and maintaining a proper weight, getting sufficient exercise and sleep, and other lifestyle changes. The digital hypertension treatment that this DTx app provides through the use of an advanced bidirectional algorithm represents a new field for hypertension treatment, and is expected to play a pivotal role in providing medical care tailored to the individual, and in promoting drug-free treatments that do not rely on medications.
Kohta Satake, CEO and Practicing Doctor
We have expanded our focus to encompass algorithm development to provide personalized healthcare advice based on medical evidence. The more data provided by the patient, the more the advice given is specifically tailored to the patient’s condition. We view the popularization of digital therapeutics for hypertension as having the potential to alter hypertension treatments for the better, as well as greatly contribute to reducing medical care expenses. Following our nicotine dependency therapeutic app “CureApp SC”, which was the first app of its kind to be covered by insurance in Japan, we also look to receive regulatory approval and insurance coverage for our hypertension therapeutics app.
About CureApp, Inc.
CureApp, Inc. is a MedTech venture that conducts research and development into the creation of medical device programs which apply advanced software technology and medical evidence to treat illnesses, with the intent of manufacturing and distributing them. We are hard at work developing “digital therapeutics” - apps used to treat illnesses - in order to become the first in Japan to establish a new healthcare service centered on “creating new therapeutic effects through technology.” In August 2020, the nicotine dependency treatment app and CO checker, “CureApp SC,” became the first therapeutic app to receive regulatory approval in Japan, and prescriptions began as a treatment covered by insurance in December of the same year.
In addition to the hypertension therapeutic app, we are currently pursuing research and development into various other digital therapeutics apps. These include a nonalcoholic steatohepatitis (NASH) therapeutic app jointly developed and currently undergoing clinical trials with the University of Tokyo Hospital, joint research on an app with the National Hospital Organization Kurihama Medical and Addiction Center, and a patient support app for cancer patients being jointly developed with DAIICHI SANKYO COMPANY, LIMITED.
We also draw upon the knowledge accumulated through the development of these therapeutic apps for medical institutions to provide the “ascure Smoking Cessation Program” for corporations that have been implemented at over 200 companies, health insurance associations and local municipalities.
Moving forward, we will look to sequentially roll out this Japanese-developed digital therapeutics solution worldwide.
[CureApp, Inc. Company Profile]
Representative Director and CEO: Kohta Satake
Head office: Kodenma-Cho YS building 4F, 12-5, Nihonbashi Kodenma-Cho, Chuo-ku, Tokyo, Japan
Business description: Development of medical device programs, mobile health-related services
[Jichi Medical University Overview]
Name: Jichi Medical University
Representative: Director, Toshio Oishi
Address: 3311-1 Yakushiji, Shimotsuke-shi, Tochigi-ken, Japan
[For research inquiries]
Department of Cardiovascular Medicine, Jichi Medical University
Professor Kazuomi Kario
Ph: +81 285-58-7538 E-mail: firstname.lastname@example.org
[For inquiries regarding therapeutics apps]
PR Representative, Yuuki Mishima
Ph: +81 3-6231-0183 E-mail: email@example.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
XPRIZE and Musk Foundation Announce Guidelines and Open Registration for $100M XPRIZE Carbon Removal23.4.2021 01:23:00 CEST | Press release
XPRIZE, the global leader in designing and implementing innovative competition models to solve the world’s grand challenges, today announced the official launch of $100 Million XPRIZE Carbon Removal with the opening of team registration and the release of the competition guidelines. The announcement comes shortly after Peter H. Diamandis,XPRIZE founder and executive chairman, and Elon Musk sat down for a live stream hosted on Twitter to discuss the importance of spurring carbon removal solutions, the climate crisis, and the launch of the largest incentive prize in history. The conversation was followed by a virtual question and answer hosted by Marcius Extavour, vice president of climate and environment at XPRIZE, and XPRIZE’s chief impact officer, Zenia Tata. Funded by the Musk Foundation, $100M XPRIZE Carbon Removal is aimed at tackling climate change by asking global innovators to develop solutions that can pull carbon dioxide directly from the atmosphere or oceans and lock it away
Verimatrix To Participate in SportsPro Live Virtual Panel: How To Transform Physical Spaces into Digital Ecosystems22.4.2021 17:45:00 CEST | Press release
Regulatory News: Verimatrix, (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Lu Bolden, Chief Revenue Officer, is slated to participate in a SportsPro Live virtual panel discussion from 9:10 to 9:55 a.m. Central Time on Thursday, April 29. The event, which unites sports and technology professionals from across the globe, aims to prepare the industries for the future of sport. Bolden’s panel is slated to take place in the South Stand and discuss how technology can connect the in-venue experience to create more revenue opportunities. The group, moderated by Mike Bohndiek, CEO of PTI Digital Group, will also discuss what strategies and technologies can best deliver the new digital experiences. Other speakers on the panel include: Michael Cole, Chief Technology Officer, PGA European Tour and Ryder Cup Europe Adam Heintz, Senior Vice President, Business Intelligence, Monumental Sports & Entertainment “T
Rajeev Bhalla Named Director of Board at Next Level Aviation22.4.2021 17:39:00 CEST | Press release
Seasoned senior finance executive Rajeev Bhalla has been named a Director of the Board at Next Level Aviation, a leader in the aerospace used serviceable materials (USM) market. He brings wide-ranging financial, operational, and strategic expertise to the company as it plans substantial growth in the coming years, both organically and through acquisition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210422005834/en/ Rajeev Bhalla has been named Director of the Board of Next Level Aviation. He will help guide the company’s planned growth in the coming years, both organically and through acquisition. (Photo: Business Wire) Bhalla’s background includes demonstrated discipline and expertise in finance, governance, and team development. This comes through current work as a Cerberus Operating Partner, board of director roles as well as experience in a number of successful companies. Notably, those include: Circor International,
Medical Aesthetic Products’ Manufacturer Croma-Pharma Launches “Croma is More” E-Learning Series for Health Care Professionals22.4.2021 17:00:00 CEST | Press release
Croma-Pharma GmbH (Croma) always strives to support physicians in their work in the best possible way. For this reason, the company has developed an interactive e-learning platform with continuing education offerings for physicians working in the field of minimally invasive aesthetic. In this way, Croma aims to help health care professionals achieve sustainable growth and success in their medical clinics/practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210422005727/en/ Social Media Training for Health Care Professionals Copyright: Croma-Pharma GmbH (Graphic: Business Wire) Medical professionals can choose from a broad variety of different formats: Social Media & Online Marketing Facial Anatomy Workshops Aesthetic Startup Academy Aesthetic Excellence A variety of topics is presented by Industry experts. All the content comes with lifetime access hence the health care professionals can learn on their own schedule and
PerkinElmer Supports PROXIDRUGS Consortium Aimed at Advancing Targeted Protein Degradation/PROTAC Drugs22.4.2021 16:44:00 CEST | Press release
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs (PROteolysis Targeting Chimeras). PROTACs are a new class of drugs that take advantage of the body’s own cell protein recycling system to fight disease by tapping into the 80% of disease-relevant proteins that are currently untargeted by today’s available therapeutics. Led by Goethe University in Frankfurt, Germany, the Consortium includes researchers from the Technical University of Darmstadt, the Fraunhofer Institute for Translational Medicine and Pharmacology, and global pharmaceutical companies based in Frankfurt’s Rhine-Main region. The research project, starting October 2021, aims to streamline novel drug target validation by putting disease-relevant proteins in close proximity with key enzymes (su
Xsolla Acquires Slemma, an Advanced Data Analytics and Visualization Company22.4.2021 16:00:00 CEST | Press release
Xsolla, the video game commerce company powered by its Transaction Engine and Business Engine to help developers and publishers market, sell, connect and optimize their games globally, has announced the acquisition of Slemma, an advanced data analytics and visualization reporting platform. The web-based tools allow users to create simple, easy-to-use and dynamic data reports with customizable dashboards. Xsolla will integrate Slemma’s product suite into the Publisher Account to provide clients with next-level data visualizations, even connecting to third party tools and services including Amazon RDS, Microsoft Azure, Google Analytics, Facebook, Twitter, Zendesk, Salesforce and many more. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210422005443/en/ Xsolla acquires Slemma, a robust data analytics and visualization platform. (Graphic: Business Wire) “Everything we do at Xsolla focuses on providing the best experience, tools
Serie A Club Parma Calcio Signs Deal with Stats Perform for Access to the Most Sophisticated Player Identification Tool—Edge Recruitment22.4.2021 15:49:00 CEST | Press release
Today, Stats Perform, the sports tech leader in data and AI, announced a deal with Italian football club Parma Calcio, recently purchased by Iowa-based Krause Group, which will see the Serie A side become the first club worldwide to access the innovative Edge Recruitment platform, the industry’s most sophisticated player identification tool. Since the emergence of technical scouting during the mid-2000s, recruitment analysts have been using data to assess prospects through the lens of traditional on-field position labels. Launched earlier this season, Edge Recruitment introduces a new method of assessing players, applying multiple AI-powered models to profile players based on their role in a team. At the heart of Edge Recruitment is Role Discovery, a model which detects 18 different types of role all over the pitch based on a player’s spatial tendencies, contributions to different phases of play, possession involvement, distribution and shooting tendencies. Through applying Role Discov
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom